Revance Therapeutics, Inc.
RVNCDelisted Feb 6, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479290
Revance Therapeutics, Inc. was delisted on Feb 6, 2025; its insiders filed their last Form 4 on Feb 6, 2025; 174 institutions reported holding it in 13F filings for Q4 2024, worth $249.2M in total; Fairfax Financial was the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Revance Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 173
- −14 vs. Q1 2024
- Shares held
- 81.4M
- −1.70M (−2.0%) vs. Q1 2024
- Total value
- $209.3M
- −$199.3M (−48.8%) vs. Q1 2024
- New holders
- 27
- 63 more added
- Sold out
- 41
- 42 more reduced
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RVNC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 2 | $425.0K |
| Q4 2024 | 174 | $249.2M |
| Q3 2024 | 201 | $429.9M |
| Q2 2024 | 173 | $209.3M |
| Q1 2024 | 188 | $409.4M |
| Q4 2023 | 193 | $636.4M |
| Q3 2023 | 187 | $893.1M |
| Q2 2023 | 215 | $2.07B |
| Q1 2023 | 217 | $2.46B |
| Q4 2022 | 193 | $1.36B |
| Q3 2022 | 182 | $1.82B |
| Q2 2022 | 161 | $774.3M |
| Q1 2022 | 156 | $1.06B |
| Q4 2021 | 151 | $864.7M |
| Q3 2021 | 159 | $1.53B |
| Q2 2021 | 161 | $1.60B |
| Q1 2021 | 149 | $1.53B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Revance Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −13,931−100.0% | Sold out |
| Accredited Investors Inc. | 0 | $0 | 0.00% | −12,845−100.0% | Sold out |
| Clarity Capital Partners LLC | 0 | $0 | 0.00% | −12,082−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −11,551−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −3,633−100.0% | Sold out |
| Riverview Trust Co | 0 | $0 | 0.00% | −3,237−100.0% | Sold out |
| Future Financial Wealth Managment LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −1,030−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −210−100.0% | Sold out |
| Creative Financial Designs Inc | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −68−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |